By applying our portfolio of drug delivery technologies to cannabinoids, we will harness and enhance the potential of cannabinoids to address unmet medical needs, redefining how patients benefit from this important class of therapeutics.
Receptor Life Sciences is a biopharmaceutical company developing oral and inhaled cannabinoid medicines characterized by rapid absorption, high bioavailability and consistent dosing. Receptor’s pharmaceutical drug delivery technologies are validated by their use in FDA-approved products.
Receptor’s oral products are designed to enhance drug absorption from the GI tract, leading to improved bioavailability and reduced variability compared to existing oral cannabinoid products.
Receptor’s inhaled products combine a simple-to-use, breath-powered inhaler with dry powder formulations of cannabinoids, providing ultra-rapid, consistent and discreet delivery of cannabinoid medicines to the deep lung.
The company’s product candidates are currently in a preclinical stage of development. Check back regularly for updates to our pipeline priorities.
SEATTLE – Receptor Life Sciences (RLS) today announced the completion of a pre-investigational new drug (preIND) meeting with the U.S. Food and Drug Administration (FDA).
SEATTLE – Receptor Life Sciences announced today that the Company was granted a Schedule I research license from the United States Drug Enforcement Agency (DEA).